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Introduction 
Proton pump inhibitors are generically available in the UK and
are relatively inexpensive. As a consequence of the low cost and
relative safety they are widely prescribed. In 2014 over 53
million items were dispensed in England at a cost of
£116,359,000 (£2.19/item).1 In 2010 around 40 million items
were dispensed. Some studies suggest 1 in 10 of the population
regularly take a PPI.2 Despite being well tolerated PPIs can cause
long-term adverse effects such as osteoporosis, hip fracture,
hypomagnesaemia, pneumonia, acute kidney injuries, myocardial
infarctions and a potentially moderate increase in Clostridium
difficile infections.3-9 PPIs are often overprescribed world-wide,
with up to 70% having no indication.10
For most patients PPIs should not be continued long-term but
stopping treatment can trigger gastric acid hypersecretion
leading to the impression that the PPI is still required to treat
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Introduction
As a consequence of the low cost and perceived safety, proton pump inhibitors (PPIs) are widely prescribed but they can cause long-
term adverse effects and are often overprescribed. For most patients PPIs should not be continued long-term as patients can become
dependent on PPIs and they are rarely stepped down/off treatment. We aimed to measure whether a dyspepsia review service could
help patients on PPIs to step down/off treatment whilst still keeping them symptom free. 
Methods
Pharmacists were provided with training on dyspepsia management. Four general practices were selected. Patients taking a PPI for
more than two months were included. A list of exclusion criteria (e.g. active ulcers, newly initiated) was applied. Between six and eight
dyspepsia review clinics were run at each site. Patients were booked into a 15-minute consultation. A concordance style consultation
was held with clinicians providing information on dyspepsia management and exploring the patients’ ideas, concerns and expectations
about stepping down or stepping off treatment. A follow-up audit was performed at four months to determine if patients had
remained stepped down/off. An economic evaluation of clinic costs and drugs savings was performed.
Results
A total of 508 patients were invited to a review; 136 did not attend and 58 were excluded due to not meeting the inclusion criteria, leaving
314 patients reviewed for step-down/step-off. Successful step down/step off was achieved in 257 people (82% of those reviewed).
The total cost savings of PPIs was £7,100. The additional cost of alginates was £1,207 giving a net saving on medicines of £5,893 per
annum. Set-up costs were £1,194 and staff costs £3,524 to £5,156 giving total running costs, which vary dependent on the Agenda
for Change (AfC) grade of pharmacist involved, of £4,720 - £6,351.
Conclusion
A dyspepsia review clinic is cost-neutral to run but, given that many patients are on polypharmacy, PPI step down might best be
considered as part of a holistic medication review clinic.
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an underlying problem.11 Patients could, therefore, become
dependent on PPIs, which may explain why the numbers of
items dispensed increases year on year. An additional
explanation for the growth of PPI use is that reviews of PPIs are
not occurring in general practice. Dyspepsia is not a long-term
condition included in the Quality and Outcomes Framework
(QOF - the annual reward and incentive programme detailing
English GP practice achievement results).12 Consequently, PPIs
are less likely to be subject to an annual review. If prescribers
also consider them to be cheap and safe and patients do not
wish to stop taking them for fear of return of symptoms
we have perfect conditions for unrestricted long-term
prescribing. The National Institute of Health and Clinical
Excellence (NICE) has produced guidance on the management
of dyspepsia that advocates limiting the exposure to long-term
prescribing of PPIs.13
We aimed to measure whether a dyspepsia review service could
help patients on PPIs by stepping down or stepping off
treatment whilst still keeping them symptom free. As the unit
cost of PPIs is low we also wanted to perform an economic
analysis of the cost-benefit to the National Health Service (NHS)
of dyspepsia clinics. The specific objectives were to:
• identify patients prescribed PPIs as repeat medication
• determine the reason for the prescription for each patient
• identify those patients in whom it would be appropriate to
step down treatment from a high dose* to a maintenance
dose
• identify patients in whom stopping the PPI may be
appropriate
• agree with patients a care plan for stepping down or
stopping PPI treatments
• quantify the cost-benefit of the service.
* High dose is defined as omeprazole 40mg, 20mg, pantoprazole 40mg,
lansoprazole 30mg, esomeprazole 40mg, 20mg and rabeprazole 20mg.
Maintenance dose is defined as omeprazole 20mg, pantoprazole 20mg,
lansoprazole 15mg or rabeprazole 10mg.
Method 
Four practices in Bradford, UK were purposively selected to run
the clinics. These practices represented a wide demographic of
social and ethnic types. Searches were run on the practice’s
clinical systems to identify all patients prescribed a PPI as a long-
term (repeat) medicine. From the lists the following inclusion
and exclusion criteria were applied to identify patients suitable
to invite. 
Inclusion criteria
All patients taking a PPI for more than two months with an
active prescription. 
Exclusion criteria 
• Patients on healing doses of PPIs < 1 month for
uninvestigated dyspepsia.
• Patients on maintenance doses of PPIs < 1 month for non-
ulcer dyspepsia.
• Patients on healing doses of PPIs < 2 months for GORD/peptic
ulcer disease.
• Patients currently on H Pylori eradication therapy.
• Patients under review at a GI clinic or awaiting referral.
• Patients awaiting gastroscopy or review.
• Zollinger-Ellison Syndrome.
• Patients > 90 years old.
• Patients with terminal illness.
• Patients with grade 3 or 4 oesophagitis.
• Patients on high dose steroids with life threatening or
chronic illness e.g. patients awaiting transplant, post-
transplant patients.
• Patients receiving immune-suppression therapy.
• Patients undergoing chemotherapy or radiotherapy.
• Patients with oesophageal strictures or oesophageal dilation.
• Patients with a history of oesophageal varices.
• Patients with ALARMS signs and symptoms  i.e. Anaemia,
Loss of Weight, Anorexia, Recent onset of progressive
symptoms, Melena, Swallowing difficulties
Available resources allowed between six and eight dyspepsia
review clinics to be run at each site. As a result, not all patients
could be invited to the clinics. Patients fitting the inclusion
criteria were phoned by practice reception staff and booked into
a 15-minute consultation at the general practice.
Clinic reviews 
Pharmacists running the clinics were provided with training on
dyspepsia management by a nurse experienced in dyspepsia
review clinics and a GP with a Special Interest in
gastroenterology (GPwSi Gastro). Training consisted of a half-
day session on the management of dyspepsia and how to step
down PPI treatments followed by mentoring of the pharmacists
in their first dyspepsia clinic. The clinics were held between
January and May 2015.
Clinic appointments were set at 15 minutes with 20 per day. At
the review the clinician established the patients understanding
of the PPI indication and checked in the patient’s record that the
clinical circumstances pertaining to the use of PPI had not
altered since the invite. 
A concordance style consultation was then held where the
clinician provided information on dyspepsia management
and explored patients’ ideas, concerns and expectations about
stepping down or stepping off PPI treatment. If a patient
agreed to step-down/step-off the patient’s GP was asked to
alter the repeat prescription. Where alginate therapy was
required to ‘bridge’ the time period when acid hypersecretion
(acid rebound) might be expected from stopping a PPI then the
GP was asked to generate a prescription. Patients were also
given advice and a leaflet on lifestyle advice (e.g. diet and
weight loss).
Patients attending clinics were asked to complete a
questionnaire about their symptom control. These were posted
to patients at the end of the clinic with a stamped, addressed
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envelope so it could be posted back anonymously. The
questionnaire asked questions about whether the patient now
had a better understanding of their condition, whether they
now felt more in control of their condition and how well their
symptoms were now controlled.
A follow-up audit of the clinic record was performed four
months after the clinic on patients who had agreed to step
down/step off to determine if they had remained on lower
doses or were now off PPIs and to measure the change in
alginate prescribing. This was done by checking clinical records
for PPI (type and dose) and alginate prescription ordering.
Economic evaluation 
The costs of screening lists of people prescribed PPIs to find
suitable patients to invite was based on a mid-point Band 4
pharmacy assistant. Based on previous experience it was
assumed that 250 records would need to be reviewed to find
150 suitable to invite and that screening could be done at a rate
of 10 records per hour.
Suitable patients were invited by letter. An assumption was
made that four hours of pharmacist assistant time was required
to prepare and send out 250 invite letters by second class post.
The costs of a pharmacist to run the clinic was based on Agenda
for Change (AfC) banding taken from the lower end of Band 6
to the top of Band 8B. Pharmacist costs were based on 15
minute appointments with two clinic sessions per day and 10
patients per clinic.14
Medicine costs were taken from the Drug Tariff.15 If a PPI was
stepped down or stepped off or the patient had remained on at
the lower dose or off treatment four months later the
assumption was made that this was a long-term change and the
medicine cost change based on one year of treatment. Alginate
costs were calculated on the actual number of bottles ordered.
Results 
A total of 1,000 patients prescribed a PPI were screened for
suitability to receive an invite. A total of 492 patients were
excluded before inviting, leading to 508 people being invited.
At the clinic 136 patients did not attend and 58 were excluded
because they did not meet the inclusion criteria, leaving 314
patients reviewed for step-down/step-off.
The outcome of the reviews is shown in Table 1. Successful step
down/step off was achieved in 257 people (51% of those
invited and 82% of those who attended and were reviewed).
Economic costs 
The total cost savings on PPIs at the six month review was
£7,100. The additional cost of alginates was £1,207, giving a
net saving on medicines of £5,893 per annum. This equates to
£11.60 and £18.70 savings for patient invited and attended
respectively.
The costs of screening of records and inviting patients and
running the clinics are shown in Table 2.
Patient feedback on symptom control 
Patient feedback on their symptom control as a result of
attending the clinic is shown in Figure 1. A total of 216
questionnaires were administered to patients and 89 (41%)
were complete. 
Discussion 
Patients who attended a dyspepsia review clinic were very likely
to have a step down of their PPI and to remain stepped down.
These findings reflect those found previously.16-21 A previous
study of PPI medicines optimisation reviews was able to show
that the practices that reviewed their PPIs also achieved a
reduction in upper gastro-intestinal (GI) referrals by 65% and a
reduction in upper GI endoscopies by 82%.16 This unexpected
Outcome                      
Stepped down
Stepped off
Refused to step down or off
Did not attend 
Did attend but did not meet
criteria
Reverted back at follow up
Had Left list or died at 
follow up
Total
Number achieving
outcome
221
36
23
136
58
18
16
508
Proportion of those invited
(n= 508)
44%
7%
4.5%
27%
11%
3.5%
3%
100%
Proportion of those
reviewed (n= 314)
70.5%
11.2%
7.1%
NA
NA
6.2%
5.0%
100%
Table 1: Outcome of the reviews
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result was attributed to the education of patients and practice
staff about dyspepsia management, reduced non-steroidal anti-
inflammatory (NSAID) use or possibly increased/optimised PPI
use in at- risk patients.16 Whilst the impact on referral rates was
not measured in this study, it is possible that a similar result
could be achieved due to the education of patients and staff in
the same way.
The numbers of patients providing postal feedback on their
symptom control as a result of attending the clinic was 89 (41%
response rate). It may be that those who were satisfied with the
clinic did not feel the need to respond. Most patients
commented that they ‘neither agreed/disagreed’ or ‘agreed’
with the statements (Figure 1). Around half of those who
responded felt their symptoms had improved i.e. 22/40 (55%).
However, half ‘disagreed’ or ‘totally disagreed’ showing that
step down did not suit all patients. We do not know, however,
if their symptoms worsened but, at review, only 6% had
reverted back to their original dose. This shows the difficulty
clinicians face when attempting to deprescribe or step down
already established treatments where the patient may not want
to undergo a change.
Prescriptions for non-attenders were not analysed so it is not
known if any changes were made to their prescriptions without
the intervention.
Item                      
Records screened
Cost per hour of Band 4
midpoint (before on-costs)
Cost at 10 records  per hour
Patients invited
Time needed to send out
letter
Cost of sending letters with a
second class stamp
Total invite costs
Data
935
£10.79
£874.23
442
8 hours
£320.42
£1,194.65
Item
Pharmacist cost per day (range
Band 6 to 8b) before on-costs
Room rent based on four hour
clinic session (£10/hour)
Number of clinics held
na
na
na
Total clinic costs
Data
£101.10 to £221.62
£80.00
£ 27
na
na
na
£3,525 to £5,156
Screening records/inviting patients Clinic costs
Table 2: Economic costs of running the clinics
Figure 1: Patient feedback on symptom control
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Whilst it is possible to step down PPI doses and step off PPIs,
prescribing in England continues to increase.1,2 The likely
explanation for an increase in prescribing volume is that patients
are being initiated on PPIs and that patients currently prescribed
PPIs are not having treatment stopped at the end of a course.
PPIs are often prescribed for non-ulcer dyspepsia, an unlicensed
indication in which PPIs are mostly ineffective.13 NICE
recommend that, for Gastro Oesophageal Reflux Disease
(GORD) and peptic ulcers, treatment doses are for short courses
followed by a step down or off.13
One explanation as to why PPIs are maintained as repeat
prescriptions is that they are perceived by prescribers to be
relatively harmless, highly effective and low cost. However,
whilst the unit cost of PPIs is low the cost of treating adverse
events can be high. For example, the mean cost of a hospital
admission for bacterial intestinal infection is £3,819, for a
fracture of femur £6,312 and for a myocardial infarction
£3,571.22 Estimates of the numbers needed to harm (NNH) from
adverse effects with PPIs is shown in Table 3.
In the busy environment of general practice there may also be a
reluctance to create potentially more work by reviewing PPIs.
We have found a similar problem with the long-term prescribing
of antidepressants where there is a reluctance by both the
patient and the GP to discuss discontinuation of the medication
because of fears about the consequences of doing so.27 We
have also found that when opioids are prescribed for non-
cancer pain, where opioids are largely ineffective, they are often
continued long-term.28
Whilst we found that the majority of patients who attended
could successfully have a step-down the running of dyspepsia
clinics requires an investment in clinician and patients’ time and
resources. Our findings show that stand-alone dyspepsia clinics
have set-up costs of £1,195 and staff costs of £3,525 to £5,156,
dependent on the AfC grade of pharmacist involved. This gives
total costs of £4,720 - £6,351 compared to savings made from
step down of PPIs after allowing for additional alginate costs
(£5,893). Quality of life scoring was not conducted. 
Stopping PPIs can help reduce and could reduce costs to the
NHS of these associated conditions such as Acute Kidney
Infection, C difficile, pneumonia and osteoporosis, which may
worsen with a PPI (Table 3).23,24,25,26 This significantly helps
strengthen the rational for encouraging dyspepsia review clinics.
It is possible to estimate the cost implications of the current
prescribing of PPIs at practice or CCG/HB level. Based on
published clinical incidence data and Hospital Episodes Statistics
(HES) data to give an indication of the complication related cost
savings. The potential savings on avoidance of complications is
based on incidence of such complications in patients on PPIs
and what reduction in these complications is expected if a
proportion of patients are stepped off a PPI. Supporting clinical
evidence is shown in Table 3.
It was also identified through a baseline audit of PPI patients16
that patients were found to be taking an average of seven
medications including their PPI, with 79% on four or more
medications, making this group an ideal target for
polypharmacy medicines optimisation reviews.
Given that PPI reviews are important, how could they be
achieved? There are three potential models for reviewing and
stepping down PPIs that could apply to routine general practice
care in the UK (Table 4). This study has demonstrated the benefit
of having a pharmacist run dyspepsia clinics but including a
dyspepsia review as part of a practice pharmacist holistic
medication review may provide additional benefit. Dyspepsia is
commonly found in patients who also have comorbidities
such as diabetes, cardiovascular disease and depression.29 PPIs
could therefore be used as an ‘index drug’ to target patients
for multi-morbidity polypharmacy reviews. The key to success
would be training for pharmacists on dyspepsia reviews.
When a medicine is prescribed often, only the unit cost of the
medicine is considered as the cost but there are other associated
costs with prescribing such as initial diagnosis,10 decision making
about the best treatment option, agreement with the patient
about their preferred choice of treatment, review of efficacy and
adverse effects on an ongoing basis.
Conclusion  
In the case of PPIs it is our experience that little or no time is
given to patient involvement and development of self-care in
treatment decision or ongoing review, which makes these
treatments less expensive to prescribe but is also resulting in the
large rise in PPI prescribing across the UK. Whilst a ‘stand alone’
dyspepsia review clinic is cost effective, it could be a more cost
Diagnosis
Hospital-acquired pneumonia (HAP)
Community-acquired C. difficile
Hospital-aquired C. difficile
Hip fractures
Acute Kidney Injury
Acute interstitial nephritis
Numbers needed to harm (NNH)
200 (relates to all acid suppressing drugs)23
89924
67 (unselected hospital admissions)24
1,96025
120 in patients aged 66 years and above26
4,761 in patients aged 66 years and above26
Table 3: Estimates of numbers needed to harm
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Method                      
Stand-alone dyspepsia clinics
Inviting in individual ‘high risk’
patients for GP or practice
pharmacist holistic medication
review.
GP or practice pharmacist
reviews as part of a multi-
morbidity holistic review
Description of method
Patient on PPIs identified and
invited into a dyspepsia
review clinic.
Patients on PPIs are invited in
for a holistic medication
review of all of the medicines
and medicine needs, which is
done at their normal annual
or biannual medication
review date.
Focus is on patients with
polypharmacy and patients
who are on high risk
medicines such as NSAIDs,
anticoagulants, DMARDs, etc
In this type of review patients
with multi-morbidity and
polypharmacy are invited in
for a review of all of the
medical conditions rather
than piecemeal reviews of
individual conditions. 
At the multi-morbidity review
the pharmacist concentrates
on reviewing and optimising
the medicine for each
condition including for
dyspepsia. GPs and nurse
concentrate on clinical
assessments and diagnosis of
new problems.
Advantages
Step down rate for patients
who attend is high.
Patients given quality time to
explain dyspepsia and self-
management, which could
improve long-term quality of
life.
Staff running clinic are
trained and skilled in
dyspepsia reviews.
Patients gain more from a
holistic review than just from
a review of one of their
medicines. 
Patients would be seen
anyway so does not unduly
inconvenience them.
Dyspepsia can be reviewed
within the context of the
patient’s medical conditions
and wishes for future care.
Patients gain more from a
holistic review than just from
a review of one of their
medicines. 
Patients would be seen
anyway so does not unduly
inconvenience them.
Disadvantages
Resources required to
identify and invite patients.
High ‘DNA’ rate.
Inconvenience for patients as
only having one condition
reviewed and they may not
consider it a problem. 
Not a cost-effective model of
care.
GPs and pharmacists are not
skilled to do dyspepsia
reviews and training would
be necessary.
Behaviour change techniques
would need to be applied to
motivate and remind staff to
review PPIs.
Sufficient time would need
to be set aside to provide a
useful review that engages
the patient.
It may not be possible
logistically to invite in all PPI
patients, especially if not on
other medicines that would
warrant a face-to-face
review.
Multi-morbidity reviews are
not yet widely adopted into
the NHS and best models of
delivery have yet to be tested
and established.
Table 4: Potential models for reviewing and stepping down PPI doses showing
advantages and disadvantages of each approach
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effective approach, and less inconvenient for patients, if PPI
reviews formed part of a holistic medication review. Clinical
Pharmacists in general practice should be trained on how to
undertake dyspepsia reviews. 
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